fuzzy, i as well agree with you as well. I do not think the type of company like Cencora would get in bed with Zenith if they didn't see the  expectation was that deal was not occuing in the next 3 to 6 months. My take from the AGM presentation is that the initial trial results on the NUT Carcinoma is showing very very good results at a 50% ORR. It would seem to me that with those results Zenith maybe applying for an orphan indication fast track therapy/breakthrough therapy for NUT Carcinoma for drug registartion. Thats my take on the presentation for an upcoming BP deal/buyout if that occurs thus Cencora involement over past 2 months ....  hope spring eternal....